

Cardiac Biomarkers Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 200 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Global Cardiac Biomarkers Market Report and Forecast 2024-2032?

The global cardiac biomarkers market was valued at approximately USD 11.35 billion in 2023. The market is projected to grow at a CAGR of 9.90% from 2024 to 2032, reaching an estimated value of around USD 26.55 billion by 2032. This growth is driven by the rising prevalence of cardiovascular diseases, advancements in diagnostic technologies, and increased demand for precise cardiac health monitoring, supported by healthcare investments and technological innovations.

Global Cardiac Biomarkers Market Analysis

The global cardiac biomarkers market is expanding due to the increasing prevalence of cardiovascular diseases and the advancement of diagnostic technologies. Cardiac biomarkers are critical for the early detection, diagnosis, and management of heart conditions such as myocardial infarction and heart failure. These biomarkers provide essential information for assessing cardiac health and guiding treatment decisions, driving the growth of the market. Enhanced sensitivity and specificity of diagnostic tests are further contributing to market expansion.

Market Driver

- ☐ **Rising Prevalence of Cardiovascular Diseases:** The increasing global incidence of cardiovascular diseases such as myocardial infarction, congestive heart failure, and acute coronary syndrome is a significant driver for the cardiac biomarkers market. The need for early diagnosis and effective management of these conditions is fueling demand for advanced diagnostic tools.
- ☐ **Technological Advancements in Biomarker Testing:** Continuous innovations in diagnostic technologies, including the development of highly sensitive and specific biomarkers, are enhancing the accuracy and reliability of cardiac diagnostic tests. These advancements are driving market growth by providing better tools for early detection and monitoring of cardiac conditions.
- ☐ **Growing Awareness and Early Diagnosis:** Increasing awareness about the importance of early diagnosis and intervention for cardiac diseases is boosting the demand for cardiac biomarkers. Public health initiatives and educational campaigns are encouraging individuals to seek timely diagnostic testing, contributing to market expansion.

Market Challenges

- ☐ **High Cost of Diagnostic Tests:** The high cost associated with advanced cardiac biomarker tests can limit their accessibility, particularly in low-resource settings. Efforts to reduce costs and make these diagnostic tools more affordable are essential for

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

broader adoption.

- Regulatory and Reimbursement Issues: Navigating the complex regulatory landscape and securing reimbursement for cardiac biomarker tests can be challenging. Variability in regulatory requirements and reimbursement policies across different regions can hinder market growth.
- Limited Infrastructure in Developing Regions: Inadequate healthcare infrastructure in developing regions can restrict the adoption of advanced cardiac biomarker tests. Investment in healthcare facilities and training is needed to overcome this barrier and expand market reach.
- Variability in Test Accuracy: Differences in test accuracy and reliability among various cardiac biomarker products can impact healthcare providers' trust and patient outcomes. Standardizing test methods and improving product quality are crucial for addressing this challenge.

Future Opportunities

- Growth in Personalized Medicine: The shift towards personalized medicine presents significant opportunities for the cardiac biomarkers market. Tailored diagnostic and treatment plans based on individual biomarker profiles can improve patient outcomes and drive market growth.
- Expansion in Emerging Markets: Expanding into emerging markets with improving healthcare infrastructure offers substantial growth potential. Strategic investments and partnerships in these regions can increase market presence and drive sales.
- Development of Point-of-Care Testing: The development of point-of-care testing (POCT) for cardiac biomarkers can enhance accessibility and convenience for patients. POCT allows for rapid and on-site diagnostic testing, which can improve early detection and management of cardiac conditions.
- Collaboration with Digital Health Platforms: Collaborating with digital health platforms and integrating cardiac biomarkers with remote monitoring systems can enhance patient care. These partnerships can provide real-time data and insights, improving disease management and patient outcomes.

Global Cardiac Biomarkers Market Trends

- Integration with AI and Machine Learning: The integration of artificial intelligence (AI) and machine learning (ML) with cardiac biomarker testing is revolutionizing the market. AI and ML algorithms can analyze vast amounts of data quickly and accurately, identifying patterns that may be missed by human analysis. These technologies enhance diagnostic accuracy, predict patient outcomes, and enable personalized treatment plans. For instance, AI-driven platforms can assess biomarker data alongside other clinical information to provide comprehensive insights into a patient's cardiac health, driving market innovation and improving patient care.
- Adoption of High-Sensitivity Biomarkers: The adoption of high-sensitivity cardiac biomarkers is a notable trend in the market. These biomarkers can detect even minute levels of cardiac injury, allowing for earlier and more accurate diagnosis of conditions such as myocardial infarction. High-sensitivity troponins, for example, provide clinicians with critical information to initiate treatment promptly, thereby improving patient outcomes. The increasing use of these advanced biomarkers is enhancing the precision of cardiac care and driving the market's growth.
- Increase in Home-Based Testing: The trend towards home-based testing and monitoring for cardiac conditions is gaining significant traction. Advances in portable and user-friendly diagnostic devices are making it possible for patients to monitor their cardiac health from the comfort of their homes. These home-based tests provide real-time data, enabling timely interventions and continuous health monitoring. This trend is especially important for chronic disease management and post-surgery care, contributing to patient convenience and adherence to treatment plans, thus driving market growth.
- Focus on Preventive Healthcare: There is an increasing focus on preventive healthcare and early intervention in the cardiac biomarkers market. Public health initiatives and educational campaigns emphasize the importance of regular cardiac health check-ups and early diagnosis. Preventive measures, such as routine screening for cardiac biomarkers, help identify risk factors early, allowing for timely lifestyle changes and medical interventions. This proactive approach not only improves patient outcomes but also reduces healthcare costs associated with advanced cardiac disease management, thereby promoting the use of cardiac biomarkers.

Global Cardiac Biomarkers Market Segmentation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Market Breakup by Product Type

- Instrument
- Chemiluminescence Instrument
- ELISA Instrument
- Reagents and Kits

The global cardiac biomarkers market is segmented by product type into instruments, chemiluminescence instruments, ELISA instruments, and reagents and kits. Instruments include devices essential for measuring biomarker levels, ensuring precise and consistent results. Chemiluminescence instruments utilize light emission to detect biomarkers with high sensitivity, while ELISA (enzyme-linked immunosorbent assay) instruments are widely used for their accuracy and reliability in detecting specific proteins. Reagents and kits provide the necessary components for conducting these tests, including antibodies, substrates, and buffers, ensuring the accuracy and reliability of diagnostic procedures.

Market Breakup by Biomarker Type

- Creatine Kinase -MB (CK-MB)
- Troponins (T and I)
- Myoglobin
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia Modified Albumin (IMA)
- Others

The market is segmented by biomarker type into creatine kinase-MB (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNP) or NT-proBNP, ischemia modified albumin (IMA), and others. Creatine kinase-MB (CK-MB) is used to detect myocardial infarction and muscle damage. Troponins (T and I) are highly specific biomarkers for cardiac injury, crucial for diagnosing heart attacks. Myoglobin, an early marker, helps in the rapid assessment of myocardial infarction. Brain natriuretic peptide (BNP) and NT-proBNP are used to diagnose and manage heart failure. Ischemia modified albumin (IMA) indicates ischemic conditions in the heart. Each biomarker plays a critical role in diagnosing various heart conditions, providing vital information for accurate treatment decisions, and improving patient outcomes.

Market Breakup by Indication

- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Others

Cardiac biomarkers are used for diagnosing a range of heart conditions, and the market is segmented by indication into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Myocardial infarction, commonly known as a heart attack, requires specific biomarkers like troponins for early detection. Congestive heart failure diagnosis relies on biomarkers such as BNP and NT-proBNP to assess heart function and manage treatment. Acute coronary syndrome includes a spectrum of conditions associated with sudden, reduced blood flow to the heart, where multiple biomarkers are critical for diagnosis. Atherosclerosis, the build-up of fats and cholesterol on artery walls, also benefits from specific biomarker testing for early intervention and management.

Market Breakup by Application

- Hospitals

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Diagnostic Laboratory
- Speciality Clinics
- Others

The market is segmented by application into hospitals, diagnostic laboratories, specialty clinics, and others. Hospitals are major users of cardiac biomarkers for diagnosing and managing various cardiac conditions, often equipped with advanced diagnostic instruments. Diagnostic laboratories specialize in conducting a wide range of tests, including cardiac biomarker assays, providing essential diagnostic services. Specialty clinics focus on health conditions, including cardiovascular diseases, and utilize specific biomarkers to enhance patient care. The others category includes research institutions and other healthcare settings where cardiac biomarkers play a vital role in clinical studies and advanced diagnostics.

Market Breakup by Region

- North America?
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America, with its advanced healthcare infrastructure and high prevalence of cardiovascular diseases, represents a significant market. Europe follows closely with substantial investments in healthcare and growing awareness about early diagnosis. Asia Pacific is witnessing rapid market growth due to improving healthcare infrastructure and increasing healthcare expenditure. Latin America and the Middle East and Africa regions are emerging markets with growing awareness and adoption of advanced diagnostic tools, driven by rising incidences of cardiovascular diseases and improving access to healthcare services.

Global Cardiac Biomarkers Market Competitive Landscape

The global cardiac biomarkers market features several key players, including Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Creative Diagnostics, bioMerieux SA, Abbott Laboratories, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, Randox Laboratories Ltd, Agilent Technologies, Inc., BG Medicine Inc., and DiaSorin Spa. These companies are actively engaged in innovations, product development, and strategic partnerships to enhance their market position and drive growth.

Key Questions Answered in the Report

- What was the estimated value of the global cardiac biomarkers market in 2023?
- What is the expected CAGR of the cardiac biomarkers market from 2024 to 2032?
- What are the key drivers of growth in the cardiac biomarkers market?
- What challenges does the cardiac biomarkers market face?
- How do technological advancements impact the cardiac biomarkers market?
- What opportunities exist for the cardiac biomarkers market in emerging regions?
- How is the market segmented by product type in the cardiac biomarkers market?
- Which biomarker types are most used in cardiac diagnostics?
- What are the primary indications for using cardiac biomarkers?
- Which applications are driving demand for cardiac biomarkers in the market?
- How does the regional segmentation of the cardiac biomarkers market look?
- Who are some of the major players in the global cardiac biomarkers market?

Key Benefits for Stakeholders

- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the cardiac biomarkers market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the cardiac

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

biomarkers market.

- The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the cardiac biomarkers industry and its attractiveness.
- The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1□Preface
- 1.1□Objectives of the Study
- 1.2□Key Assumptions
- 1.3□Report Coverage - Key Segmentation and Scope
- 1.4□Research Methodology
- 2□Executive Summary
- 3□Global Cardiac Biomarkers Market Overview
- 3.1□Global Cardiac Biomarkers Market Historical Value (2017-2023)
- 3.2□Global Cardiac Biomarkers Market Forecast Value (2024-2032)
- 4□Vendor Positioning Analysis
- 4.1□Key Vendors
- 4.2□Prospective Leaders
- 4.3□Niche Leaders
- 4.4□Disruptors
- 5□Global Cardiac Biomarkers Market Landscape*
- 5.1□Global Cardiac Biomarkers Market: Developers Landscape
- 5.1.1□Analysis by Year of Establishment
- 5.1.2□Analysis by Company Size
- 5.1.3□Analysis by Region
- 5.2□Global Cardiac Biomarkers Market: Product Landscape
- 5.2.1□Analysis by Product Type
- 5.2.2□Analysis by Biomarker Type
- 5.2.3□Analysis by Indication
- 6□Global Cardiac Biomarkers Market Dynamics
- 6.1□Market Drivers and Constraints
- 6.2□SWOT Analysis
- 6.2.1□Strengths

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
 - 6.3.1 Political
 - 6.3.2 Economic
 - 6.3.3 Social
 - 6.3.4 Technological
 - 6.3.5 Legal
 - 6.3.6 Environment
- 6.4 Porter's Five Forces Model
 - 6.4.1 Bargaining Power of Suppliers
 - 6.4.2 Bargaining Power of Buyers
 - 6.4.3 Threat of New Entrants
 - 6.4.4 Threat of Substitutes
 - 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Cardiac Biomarkers Market Segmentation (2017-2032)
 - 7.1 Global Cardiac Biomarkers Market (2017-2032) by Product Type
 - 7.1.1 Market Overview
 - 7.1.2 Instrument
 - 7.1.2.1 Chemiluminescence Instrument
 - 7.1.2.2 ELISA Instrument
 - 7.1.3 Reagents and Kits
 - 7.2 Global Cardiac Biomarkers Market (2017-2032) by Biomarker Type
 - 7.2.1 Market Overview
 - 7.2.2 Creatine Kinase -MB (CK-MB)
 - 7.2.3 Troponins (T and I)
 - 7.2.4 Myoglobin
 - 7.2.5 Brain Natriuretic Peptide (BNPs) or NT-proBNP
 - 7.2.6 Ischemia Modified Albumin (IMA)
 - 7.2.7 Others
 - 7.3 Global Cardiac Biomarkers Market (2017-2032) by Indication
 - 7.3.1 Market Overview
 - 7.3.2 Myocardial Infarction
 - 7.3.3 Congestive Heart Failure
 - 7.3.4 Acute Coronary Syndrome
 - 7.3.5 Atherosclerosis
 - 7.3.6 Others
 - 7.4 Global Cardiac Biomarkers Market (2017-2032) by Application
 - 7.4.1 Market Overview
 - 7.4.2 Hospitals
 - 7.4.3 Diagnostic Laboratory
 - 7.4.4 Speciality Clinics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.5 Others
- 7.5 Global Cardiac Biomarkers Market (2017-2032) by Region
 - 7.5.1 Market Overview
 - 7.5.2 North America
 - 7.5.3 Europe
 - 7.5.4 Asia Pacific
 - 7.5.5 Latin America
 - 7.5.6 Middle East and Africa
- 8 North America Cardiac Biomarkers Market (2017-2032)
 - 8.1 North America Cardiac Biomarkers Market (2017-2032) by Product Type
 - 8.1.1 Market Overview
 - 8.1.2 Instrument
 - 8.1.2.1 Chemiluminescence Instrument
 - 8.1.2.2 ELISA Instrument
 - 8.1.3 Reagents and Kits
 - 8.2 North America Cardiac Biomarkers Market (2017-2032) by Biomarker Type
 - 8.2.1 Market Overview
 - 8.2.2 Creatine Kinase -MB (CK-MB)
 - 8.2.3 Troponins (T and I)
 - 8.2.4 Myoglobin
 - 8.2.5 Brain Natriuretic Peptide (BNPs) or NT-proBNP
 - 8.2.6 Ischemia Modified Albumin (IMA)
 - 8.2.7 Others
 - 8.3 North America Cardiac Biomarkers Market (2017-2032) by Indication
 - 8.3.1 Market Overview
 - 8.3.2 Myocardial Infarction
 - 8.3.3 Congestive Heart Failure
 - 8.3.4 Acute Coronary Syndrome
 - 8.3.5 Atherosclerosis
 - 8.3.6 Others
 - 8.4 North America Cardiac Biomarkers Market (2017-2032) by Application
 - 8.4.1 Market Overview
 - 8.4.2 Hospitals
 - 8.4.3 Diagnostic Laboratory
 - 8.4.4 Speciality Clinics
 - 8.4.5 Others
 - 8.5 North America Cardiac Biomarkers Market (2017-2032) by Country
 - 8.5.1 United States of America
 - 8.5.2 Canada
- 9 Europe Cardiac Biomarkers Market (2017-2032)
 - 9.1 Europe Cardiac Biomarkers Market (2017-2032) by Product Type
 - 9.1.1 Market Overview
 - 9.1.2 Instrument
 - 9.1.2.1 Chemiluminescence Instrument
 - 9.1.2.2 ELISA Instrument
 - 9.1.3 Reagents and Kits
 - 9.2 Europe Cardiac Biomarkers Market (2017-2032) by Biomarker Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.1 Market Overview
- 9.2.2 Creatine Kinase -MB (CK-MB)
- 9.2.3 Troponins (T and I)
- 9.2.4 Myoglobin
- 9.2.5 Brain Natriuretic Peptide (BNPs) or NT-proBNP
- 9.2.6 Ischemia Modified Albumin (IMA)
- 9.2.7 Others
- 9.3 Europe Cardiac Biomarkers Market (2017-2032) by Indication
- 9.3.1 Market Overview
- 9.3.2 Myocardial Infarction
- 9.3.3 Congestive Heart Failure
- 9.3.4 Acute Coronary Syndrome
- 9.3.5 Atherosclerosis
- 9.3.6 Others
- 9.4 Europe Cardiac Biomarkers Market (2017-2032) by Application
- 9.4.1 Market Overview
- 9.4.2 Hospitals
- 9.4.3 Diagnostic Laboratory
- 9.4.4 Speciality Clinics
- 9.4.5 Others
- 9.5 Europe Cardiac Biomarkers Market (2017-2032) by Country
- 9.5.1 United Kingdom
- 9.5.2 Germany
- 9.5.3 France
- 9.5.4 Italy
- 9.5.5 Others
- 10 Asia Pacific Cardiac Biomarkers Market (2017-2032)
- 10.1 Asia Pacific Cardiac Biomarkers Market (2017-2032) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Instrument
- 10.1.2.1 Chemiluminescence Instrument
- 10.1.2.2 ELISA Instrument
- 10.1.3 Reagents and Kits
- 10.2 Asia Pacific Cardiac Biomarkers Market (2017-2032) by Biomarker Type
- 10.2.1 Market Overview
- 10.2.2 Creatine Kinase -MB (CK-MB)
- 10.2.3 Troponins (T and I)
- 10.2.4 Myoglobin
- 10.2.5 Brain Natriuretic Peptide (BNPs) or NT-proBNP
- 10.2.6 Ischemia Modified Albumin (IMA)
- 10.2.7 Others
- 10.3 Asia Pacific Cardiac Biomarkers Market (2017-2032) by Indication
- 10.3.1 Market Overview
- 10.3.2 Myocardial Infarction
- 10.3.3 Congestive Heart Failure
- 10.3.4 Acute Coronary Syndrome
- 10.3.5 Atherosclerosis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.6□Others
- 10.4□Asia Pacific Cardiac Biomarkers Market (2017-2032) by Application
 - 10.4.1□Market Overview
 - 10.4.2□Hospitals
 - 10.4.3□Diagnostic Laboratory
 - 10.4.4□Speciality Clinics
 - 10.4.5□Others
- 10.5□Asia Pacific Cardiac Biomarkers Market (2017-2032) by Country
 - 10.5.1□China
 - 10.5.2□Japan
 - 10.5.3□India
 - 10.5.4□ASEAN
 - 10.5.5□Australia
 - 10.5.6□Others
- 11□Latin America Cardiac Biomarkers Market (2017-2032)
 - 11.1□Latin America Cardiac Biomarkers Market (2017-2032) by Product Type
 - 11.1.1□Market Overview
 - 11.1.2□Instrument
 - 11.1.2.1□Chemiluminescence Instrument
 - 11.1.2.2□ELISA Instrument
 - 11.1.3□Reagents and Kits
 - 11.2□Latin America Cardiac Biomarkers Market (2017-2032) by Biomarker Type
 - 11.2.1□Market Overview
 - 11.2.2□Creatine Kinase -MB (CK-MB)
 - 11.2.3□Troponins (T and I)
 - 11.2.4□Myoglobin
 - 11.2.5□Brain Natriuretic Peptide (BNPs) or NT-proBNP
 - 11.2.6□Ischemia Modified Albumin (IMA)
 - 11.2.7□Others
 - 11.3□Latin America Cardiac Biomarkers Market (2017-2032) by Indication
 - 11.3.1□Market Overview
 - 11.3.2□Myocardial Infarction
 - 11.3.3□Congestive Heart Failure
 - 11.3.4□Acute Coronary Syndrome
 - 11.3.5□Atherosclerosis
 - 11.3.6□Others
 - 11.4□Latin America Cardiac Biomarkers Market (2017-2032) by Application
 - 11.4.1□Market Overview
 - 11.4.2□Hospitals
 - 11.4.3□Diagnostic Laboratory
 - 11.4.4□Speciality Clinics
 - 11.4.5□Others
 - 11.5□Latin America Cardiac Biomarkers Market (2017-2032) by Country
 - 11.5.1□Brazil
 - 11.5.2□Argentina
 - 11.5.3□Mexico
 - 11.5.4□Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12 Middle East and Africa Cardiac Biomarkers Market (2017-2032)
 - 12.1 Middle East and Africa Cardiac Biomarkers Market (2017-2032) by Product Type
 - 12.1.1 Market Overview
 - 12.1.2 Instrument
 - 12.1.2.1 Chemiluminescence Instrument
 - 12.1.2.2 ELISA Instrument
 - 12.1.3 Reagents and Kits
 - 12.2 Middle East and Africa Cardiac Biomarkers Market (2017-2032) by Biomarker Type
 - 12.2.1 Market Overview
 - 12.2.2 Creatine Kinase -MB (CK-MB)
 - 12.2.3 Troponins (T and I)
 - 12.2.4 Myoglobin
 - 12.2.5 Brain Natriuretic Peptide (BNPs) or NT-proBNP
 - 12.2.6 Ischemia Modified Albumin (IMA)
 - 12.2.7 Others
 - 12.3 Middle East and Africa Cardiac Biomarkers Market (2017-2032) by Indication
 - 12.3.1 Market Overview
 - 12.3.2 Myocardial Infarction
 - 12.3.3 Congestive Heart Failure
 - 12.3.4 Acute Coronary Syndrome
 - 12.3.5 Atherosclerosis
 - 12.3.6 Others
 - 12.4 Middle East and Africa Cardiac Biomarkers Market (2017-2032) by Application
 - 12.4.1 Market Overview
 - 12.4.2 Hospitals
 - 12.4.3 Diagnostic Laboratory
 - 12.4.4 Speciality Clinics
 - 12.4.5 Others
 - 12.5 Middle East and Africa Cardiac Biomarkers Market (2017-2032) by Country
 - 12.5.1 Saudi Arabia
 - 12.5.2 United Arab Emirates
 - 12.5.3 Nigeria
 - 12.5.4 South Africa
 - 12.5.5 Others
- 13 Regulatory Framework
 - 13.1 Regulatory Overview
 - 13.2 US FDA
 - 13.3 EU EMA
 - 13.4 INDIA CDSCO
 - 13.5 JAPAN PMDA
 - 13.6 Others
- 14 Patent Analysis
 - 14.1 Analysis by Type of Patent
 - 14.2 Analysis by Publication Year
 - 14.3 Analysis by Issuing Authority
 - 14.4 Analysis by Patent Age
 - 14.5 Analysis by CPC Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.6□ Analysis by Patent Valuation
- 14.7□ Analysis by Key Players
- 15□Funding and Investment Analysis
- 15.1□ Analysis by Funding Instances
- 15.2□ Analysis by Type of Funding
- 15.3□ Analysis by Funding Amount
- 15.4□ Analysis by Leading Players
- 15.5□ Analysis by Leading Investors
- 15.6□ Analysis by Geography
- 16□Strategic Initiatives
- 16.1□ Analysis by Partnership Instances
- 16.2□ Analysis by Type of Partnership
- 16.3□ Analysis by Leading Players
- 16.4□ Analysis by Geography
- 17□Supplier Landscape
- 17.1□Market Share Analysis, By Region (Top 5 Companies)
- 17.1.1□Market Share Analysis: Global
- 17.1.2□Market Share Analysis: North America
- 17.1.3□Market Share Analysis: Europe
- 17.1.4□Market Share Analysis: Asia Pacific
- 17.1.5□Market Share Analysis: Others
- 17.2□Bio-Rad Laboratories, Inc .
- 17.2.1□Financial Analysis
- 17.2.2□Product Portfolio
- 17.2.3□Demographic Reach and Achievements
- 17.2.4□Company News and Developments
- 17.2.5□Certifications
- 17.3□F. Hoffmann-La Roche Ltd
- 17.3.1□Financial Analysis
- 17.3.2□Product Portfolio
- 17.3.3□Demographic Reach and Achievements
- 17.3.4□Company News and Developments
- 17.3.5□Certifications
- 17.4□Beckman Coulter, Inc .
- 17.4.1□Financial Analysis
- 17.4.2□Product Portfolio
- 17.4.3□Demographic Reach and Achievements
- 17.4.4□Company News and Developments
- 17.4.5□Certifications
- 17.5□Creative Diagnostics
- 17.5.1□Financial Analysis
- 17.5.2□Product Portfolio
- 17.5.3□Demographic Reach and Achievements
- 17.5.4□Company News and Developments
- 17.5.5□Certifications
- 17.6□bioMerieux SA
- 17.6.1□Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.6.2□Product Portfolio
- 17.6.3□Demographic Reach and Achievements
- 17.6.4□Company News and Developments
- 17.6.5□Certifications
- 17.7□ Abbott Laboratories
- 17.7.1□Financial Analysis
- 17.7.2□Product Portfolio
- 17.7.3□Demographic Reach and Achievements
- 17.7.4□Company News and Developments
- 17.7.5□Certifications
- 17.8□ Thermo Fisher Scientific Inc .
- 17.8.1□Financial Analysis
- 17.8.2□Product Portfolio
- 17.8.3□Demographic Reach and Achievements
- 17.8.4□Company News and Developments
- 17.8.5□Certifications
- 17.9□ Siemens Healthineers AG
- 17.9.1□Financial Analysis
- 17.9.2□Product Portfolio
- 17.9.3□Demographic Reach and Achievements
- 17.9.4□Company News and Developments
- 17.9.5□Certifications
- 17.10□Danaher Corporation
- 17.10.1□Financial Analysis
- 17.10.2□Product Portfolio
- 17.10.3□Demographic Reach and Achievements
- 17.10.4□Company News and Developments
- 17.10.5□Certifications
- 17.11□Randox Laboratories Ltd
- 17.11.1□Financial Analysis
- 17.11.2□Product Portfolio
- 17.11.3□Demographic Reach and Achievements
- 17.11.4□Company News and Developments
- 17.11.5□Certifications
- 17.12□Agilent Technologies, Inc
- 17.12.1□Financial Analysis
- 17.12.2□Product Portfolio
- 17.12.3□Demographic Reach and Achievements
- 17.12.4□Company News and Developments
- 17.12.5□Certifications
- 17.13□BG Medicine Inc .
- 17.13.1□Financial Analysis
- 17.13.2□Product Portfolio
- 17.13.3□Demographic Reach and Achievements
- 17.13.4□Company News and Developments
- 17.13.5□Certifications
- 17.14□DiaSorin Spa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Company News and Developments
17.14.5 Certifications
18 Global Cardiac Biomarkers Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cardiac Biomarkers Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com